X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001. The partnership will accelerate its clinical manufacturing of future mRNA-based vaccines targeting infectious diseases such as RSV and CDI.
Lead Product(s): RVM-V001
Therapeutic Area: Infections and Infectious Diseases Product Name: RVM-V001
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: GenScript ProBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 22, 2023
Details:
RVM-V001 is a mRNA-based COVID-19 vaccine candidate for which the company has secured approval from the HSA to initiate Phase 1B clinical trial in Singapore to evaluate product's safety and immunogenicity.
Lead Product(s): RVM-V001
Therapeutic Area: Infections and Infectious Diseases Product Name: RVM-V001
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
Details:
Phase 1 study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 administered as a single IM injection in healthy adults. Three dose levels will be evaluated, with progression from low- to high-dose level based on the assessment of safety and tolerability.
Lead Product(s): RVM-V001
Therapeutic Area: Infections and Infectious Diseases Product Name: RVM-V001
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
Proceeds from this will be used for preclinical and clinical development of the mRNA vaccine and therapeutics programs and building world class R&D centers and manufacturing capabilities, including R&D center in Singapore and manufacturing facilities in Singapore and China.
Lead Product(s): mRNA COVID Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Pavilion Capital
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
